A first-in-human study reported that an off-the-shelf vaccine aimed at common mutant KRAS variants can be both safe and immunologically active in people at elevated risk of pancreatic ductal adenocarcinoma (PDAC). The approach targets a core cancer driver present in the vast majority of PDACs, along with many early pancreatic precursors.

The work builds on the concept of “interception,” in which immune pressure is applied before invasive cancer fully emerges. Rather than waiting for diagnosis, the trial enrolled high-risk participants carrying hereditary predisposition or harboring suspicious pancreatic lesions such as small cysts—findings often considered surveillance triggers.

The investigational product, mKRAS-VAX, is designed to be broadly applicable by including synthetic long peptides representing six frequent KRAS mutations found in PDAC and in most associated precancerous lesions. This multi-epitope design is intended to increase the odds that a participant’s immune system can recognize relevant mutant KRAS sequences.

Twenty participants received the vaccine subcutaneously using a prime-boost regimen: priming doses at weeks 1, 3, and 5, followed by a booster at week 13. Researchers collected blood samples at multiple time points to quantify KRAS-specific T-cell responses and assess their durability.

Safety was a primary endpoint. Across participants, the vaccine was well tolerated, with no signal of severe toxicity reported in this early-phase cohort. Importantly for prevention strategies, immune responses persisted rather than fading quickly after vaccination.

After treatment, 90% of participants generated mutant-KRAS-specific effector and central memory T cells. These responses remained detectable for up to two years, consistent with the long-lived immunity that interception may require to influence the trajectory of early lesions.

With a median follow-up of 16.5 months, no participant developed cancer. As an exploratory clinical indicator, cyst outcomes were compared with those from an unvaccinated cohort of similar risk; cyst reduction or resolution occurred in 37.5% of vaccinated individuals versus 6.8% without vaccination.

The authors emphasize that the trial was not powered to prove clinical efficacy. The immune assays relied on peripheral blood, and the key question—whether vaccine-elicited T cells infiltrate precancer tissue—remains under investigation in an ongoing study.

If future larger trials confirm a link between durable KRAS-specific immunity, lesion stabilization or regression, and ultimately fewer cancers, KRAS-based vaccination could become a noninvasive preventive tool in high-risk PDAC surveillance programs.

Subject of Research: Pancreatic cancer interception using a mutant KRAS vaccine
Article Title: First-in-human Testing of a Mutant KRAS Vaccine for Pancreatic Cancer Interception in High-risk Cohorts
News Publication Date: 2026-07-16
Web References: https://clinicaltrials.gov/study/NCT05013216
References: 10.1158/2159-8290.CD-25-2245
Image Credits: Not provided
Keywords: pancreatic cancer, KRAS mutations, vaccine development, T cells, cancer interception, high-risk surveillance

Tags: cancer interception strategiesdurable immune responses in cancer preventionearly detection and prevention of PDAChereditary pancreatic cancer riskimmune monitoring in cancer vaccine trialsimmunotherapy for high-risk individualsKRAS mutation vaccinemulti-epitope vaccine designoff-the-shelf pancreatic cancer vaccinePancreatic cancer preventionsafety assessment of cancer immunizationsynthetic long peptide vaccine